Creative Biolabs CAR-T Blog

Menu

Skip to content
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News

CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology

Creative Biolabs has established CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology platform for CAR construction.

Read More

One-Stop CAR-T Therapy Development Services

Creative Biolabs provides high-quality custom service covering the entire CAR-T therapy development process to best suit our your technical, program and budget requirements

Read More

TCR Modified T Cell Development Services

Creative Biolabs focuses on the field of cancer therapy with a strong basic R & D platform that can help you with TCRs development

Read More

Oncolytic Virus Therapy Development

Creative Biolabs provides customized, standardized, and reliable and high-quality oncolytic virus therapy development services for clients globally.

Read More
22Nov/17

Revelation! CAR-T Has Its “Eyes” on Solid Tumor and the Treatment of That Would Be Possible

November 22, 2017Chimeric Antigen Receptor ResearchCAR-T, TCRbiocart

Immunotherapy has become a new hope against cancer. CAR-T cell therapy is achieved by using genetic engineering method to express chimeric antigen receptors on T cells obtained from donner patients. These chimeric antigenRead More…

22Nov/17

Comparison between CAR-T and TCR-T

November 22, 2017Chimeric Antigen Receptor Research, TCR ResearchCAR-T, TCRbiocart

As a matter of fact, tumor immunotherapy is divided into two categories. One is to show immune cells the tumor features, then direct them to locate and kill tumor cells. And anotherRead More…

22Nov/17

A New Immunotherapy Called CAR-T Will Beat Cancer Surprisingly

November 22, 2017TCR Researchbiocart

CAR-T (Chimeric Antigen Receptor T-Cell), as an immunocytotherapy regimen, has attracted a lot of attention from academics, doctors, patients, and investors worldwide. What does make it so attractive and popular? CAR-T modifies humanRead More…

22Nov/17

The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!

November 22, 2017Chimeric Antigen Receptor Research, NewsCAR-T, TCRbiocart

Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…

22Nov/17
Fig. 1 Molecular structure of chimeric antigen receptor used for CTL019 (Forsberg, 2018)

Will the First CAR-T Therapy Be Approved on July 12? —Novartis CTL019

November 22, 2017Chimeric Antigen Receptor Research, NewsCAR-T, TCRbiocart

On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluate the dataRead More…

22Nov/17

The Appearance of CAR-T

November 22, 2017Chimeric Antigen Receptor ResearchCAR-T, TCRbiocart

CAR-T (T cell chimeric antigen receptor), as an immune cell therapy has attracted worldwide attention including academics, doctors, patients, and investors. However, what’s CAR-T exactly?  What’s the background of it? What’s the currentRead More…

22Nov/17

The Exploration of CAR T Cells Validation

November 22, 2017Chimeric Antigen Receptor ResearchCAR-T, TCRbiocart

Chimeric antigen receptor (CAR) T cells have hit the cancer immunotherapy area in the past few years. ‘A CAR therapy for cancer, using a technique called adoptive cell transfer, has been approvedRead More…

22Nov/17
Fig.1 Structures of T cell receptor and chimeric-antigen receptor (Sadelain, 2017)

The Development of CAR Gene Construction

November 22, 2017Chimeric Antigen Receptor ResearchCAR-T, TCRbiocart

CAR-T is chimeric antigen receptor T cell immunotherapy, which modifies T cell receptor by CAR and transforms it into the scFV segment in the binding domain of monoclonal antibodies. A classic CAR-TRead More…

22Nov/17

The Introduction of T Cell Proliferation Assay

November 22, 2017TCR ResearchCAR-T, TCRbiocart

Cell proliferation is an important vital sign of the organism in a splitting manner. Single-celled organisms produce new individuals in the form of cell division, while a multicellular organism that produces newRead More…

22Nov/17

TCR, A New Star of Immune Cell Therapy

November 22, 2017TCR ResearchCAR-T, TCRbiocart

Immune cell therapy, the fourth major cancer treatment following surgery, radiotherapy, and chemotherapy, has been recognized as the most active and promising treatment in the comprehensive tumor treatment in the 21st century.Read More…

Posts navigation

  • « Previous
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • Next »

Categories

  • Cancer Immunotherapy
  • Chimeric Antigen Receptor Research
  • COVID-19
  • Events
  • HLA Typing
  • News
  • Oncolytic Virus Therapy Research
  • TCR Research

Recent Posts

  • CAR-T Cells Targeting PSCA Show Promise in Treating Metastatic Castration-Resistant Prostate Cancer
  • Advancements and Challenges in CAR-Macrophage Therapy: A New Frontier in Cancer Immunotherapy
  • NK Cell Surveillance Limits T Cell Responses: Implications for Cancer Immunotherapy
  • High-throughput Discovery of Tumor-Reactive T Cell Receptors: Advancing Personalized Cellular Immunotherapy
  • Overcoming Resistance: Enhancing CAR-T Therapy for AML with TP53 Mutations

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs CAR-T Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News